XML 40 R29.htm IDEA: XBRL DOCUMENT v3.20.2
Basis of Presentation and Significant Accounting Policies (Details)
3 Months Ended 6 Months Ended
Jun. 30, 2020
USD ($)
Jun. 30, 2019
USD ($)
Jun. 30, 2020
USD ($)
segment
Jun. 30, 2019
USD ($)
Apr. 23, 2020
USD ($)
Dec. 31, 2019
USD ($)
Oct. 31, 2018
Sep. 30, 2018
Dec. 31, 2017
Basis of Presentation and Significant Accounting Policies                  
Accumulated deficit $ 115,344,284   $ 115,344,284     $ 104,597,748      
Net loss 4,536,818 $ 4,944,905 10,910,238 $ 10,763,986          
Cash, cash equivalents and short term investments 47,000,000   47,000,000            
Derivative warrant liability $ 47,939   $ 47,939            
Number of operating segments | segment     1            
Maximum                  
Basis of Presentation and Significant Accounting Policies                  
Aggregate public offering price         $ 150,000,000        
At The Market Offerings | Maximum                  
Basis of Presentation and Significant Accounting Policies                  
Percentage of commission fees to sales agent         3.0        
Pelican Therapeutics, Inc.                  
Basis of Presentation and Significant Accounting Policies                  
Ownership interest in subsidiary 85.00%   85.00%     85.00%      
Pelican Therapeutics, Inc.                  
Basis of Presentation and Significant Accounting Policies                  
Percentage of voting interests acquired in acquisition             85.00% 80.00% 80.00%